Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity and Stock-Based Compensation (Tables)

v3.20.1
Stockholders' Equity and Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2020
Stockholders' Equity and Stock-Based Compensation (Tables)  
Schedule of Warrants Outstanding

 

March 31,

 

December 31,

 

Outstanding Warrants

 

2020

 

2019

 

Issued to Investors on October 25, 2013, entitling the holders to purchase 20,833 common shares in the Company at an exercise price of $138.00 per common share up to and including April 24, 2021. In 2016, 4,954 of these warrants were exchanged for common stock, and all remaining warrant holders agreed to new warrant terms, which excluded any potential net cash settlement provisions in exchange for a reduced exercise price of $75.00 per share.

 

13,665

 

13,665

 

Issued to Investors on November 17, 2014, entitling the holders to purchase 45,577 common shares in the Company at an exercise price of $138.60 per common share up to and including May 16, 2022. On June 30, 2016, the warrant holders agreed to new warrant terms, which excluded any potential net cash settlement provisions in order to classify them as equity in exchange for a reduced exercise price of $75.00 per share.

 

45,577

 

45,577

 

Issued to an investment bank and subsequently transferred to a principal of the investment bank regarding the Series B Preferred Stock investment on January 30, 2018, entitling the holder to purchase 11,119 common shares in the Company at an exercise price of $18.00 per share, up to and including January 30, 2021.

 

11,119

 

11,119

 

Total

 

70,361

 

70,361

Schedule of Share-based Compensation, Stock Options, Activity

 

Three months ended

March 31,

 

2020

 

2019

 

Research and development expenses

 

$

 

$

170,134

 

General and administrative expenses

 

6,085

 

164,879

 

Total stock-based compensation expense

 

$

6,085

 

$

335,013

Schedule of Stock option transactions of the employees

 

Options

Outstanding

 

Weighted

Average

Exercise

Price

 

Weighted

Average

Grant Date

Fair Value

 

Beginning of the period – January 1, 2020

 

518,551

 

$

21.99

 

$

15.89

 

Granted

 

 

 

 

Exercised

 

 

 

 

Forfeited

 

 

 

 

Expired

 

(1,397

)

 

519.00

 

467.31

 

End of the period – March 31, 2020

 

517,154

 

$

20.64

 

$

14.67

 

Options exercisable

 

432,281

 

$

22.59

 

$

15.93

Schedule of Non-Vested Options, Activity

 

Shares

 

Weighted

Average

Exercise Price

 

Weighted-

Average Fair

Value

Grant Date

 

Non-vested – January 1, 2020

 

84,873

 

10.73

 

5.15

 

Granted

 

 

 

 

Vested

 

 

 

 

Forfeited

 

 

 

 

Non-vested – March 31, 2020

 

84,873

 

10.73

 

5.15

Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award

 

Stock Options Outstanding

 

Stock Options Vested

 

Weighted

 

Weighted

 

Average

 

Average

 

Remaining

 

Weighted

 

Remaining

 

Weighted

 

Contractual

 

Number

 

Average

 

Contractual

 

Number

 

Average

 

Life

 

of

 

Exercise

 

Life

 

of

 

Exercise

 

Exercise Prices

 

-Years

 

Awards

 

Price

 

-Years

 

Awards

 

Price

 

$

3.82-$12.48

 

 8.88

 

225,937

 

$

 8.07

 

 9.15

 

 143,696

 

$

 6.57

 

$

12.49-$24.00

 

 7.32

 

199,790

 

$

 14.19

 

 7.31

 

 197,158

 

$

 14.21

 

$

24.01-$72.00

 

 5.64

 

65,333

 

$

 55.07

 

 5.64

 

 65,333

 

$

 55.07

 

$

72.01-$240.00

 

 5.07

 

24,526

 

$

 75.59

 

 5.07

 

 24,526

 

$

 75.59

 

$

240.01-$492.00

 

 0.76

 

1,568

 

$

 361.43

 

 0.76

 

1,568

 

$

 361.43

 

Total

 

 7.66

 

517,154

 

$

 20.64

 

 7.52

 

 432,281

 

$

 22.59